ONCT News and Press, Oncternal Therapeutics Inc. From 02/01/22

Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...

Session will include a discussion of the treatment landscape for Mantle Cell Lymphoma, including potential role of Zilovertamab, Oncternal’s ROR1 antibody ready for Phase 3 in R/R MCL, with recent FDA agreement on study design The discussion will also cover perspectives o...

The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib The FDA also provided positive feedback on the proposed key clinical and reg...

Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021 Objective response rate (ORR) of 81% (21 of 26 evaluable patients) observed for heavily pre-treated pa...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1...

Two new Breakout Stocks for Week 46 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 24 weeks out 45 weeks this year in nega...

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will present and participate virtually at the 12 th Annual Jefferi...

Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q3 2021 Earnings Call Nov 04, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q3 2021 Earnings Call Tran...

Oncternal Therapeutics, Inc. (ONCT) Q3 2021 Earnings Conference Call November 04, 2021 05:00 PM ET Company Participants Rich Vincent - Chief Financial Officer James Breitmeyer - President & Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj Sin...

Oncternal Therapeutics (NASDAQ:ONCT): Q3 GAAP EPS of -$0.19. Revenue of $2.1M (+255.9% Y/Y) beats by $1.29M. Press Release As of September 30, 2021, we had $97.4M in cash and cash equivalents. The company believes these funds will be sufficient to fund our operations into 2023. For further ...